Results from the phase III CheckMate -577 trial demonstrated that adjuvant treatment with Opdivo (nivolumab) showed a statistically significant and clinically meaningful improvement in disease-free survival, the trial’s primary endpoint, compared to placebo in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and tumor resection.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
